Cibus Names Agricultural Biotechnology Leader Craig Wichner as Chief Executive Officer to Accelerate Growth and Value Creation
Rhea-AI Summary
Cibus (Nasdaq: CBUS) announced a leadership transition under its succession plan. Board member Craig Wichner becomes Chief Executive Officer, while Peter Beetham continues as President and Chief Operating Officer after serving as Interim CEO.
Both Wichner and Beetham resigned from the Board. According to Cibus, Beetham helped raise over $62 million in new investment and advance initial commercialization targets. Wichner, founder of Farmland LP, brings experience overseeing more than $350 million in farmland assets and 19,000 acres.
Positive
- Raised over $62 million in new investment during the past fifteen months
- CEO succession plan installs leader with experience managing $350 million in farmland assets
Negative
- None.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 14 | Q1 results update | Positive | -7.1% | Reported lower net loss, cost cuts, cash runway into late Q1 2027. |
| May 04 | Commercial milestone | Positive | +2.8% | Transferred gene-edited rice traits to partner Interoc for testing and production. |
| Apr 30 | Earnings call notice | Neutral | +3.6% | Announced date and logistics for the Q1 2026 results call and webcast. |
| Apr 15 | Board appointment | Positive | +1.4% | Elected Thomas Urban to board, adding agribusiness and M&A experience. |
| Mar 26 | Equity offering | Negative | -25.8% | Priced underwritten stock offering with substantial expected gross proceeds. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Most prior headlines saw price reactions broadly aligned with the news tone, except a positive Q1 update that drew a negative reaction.
Over the last few months, Cibus has combined financings, execution updates, and governance changes. On Mar 26, it priced a stock offering that coincided with a -25.78% move. Governance steps included adding Thomas Urban to the board on Apr 15 and scheduling Q1 results for May 14, both followed by modest gains. Q1 results on May 14 showed reduced losses and cost cuts but the stock fell 7.09%. Today’s CEO appointment continues this focus on leadership and commercialization.
Key Terms
shelf registration regulatory
at-the-market program financial
restricted stock units financial
form 4 regulatory
going-concern risk financial
herbicide tolerance traits technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, June 08, 2026 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the “Company” or “Cibus”), a leading agricultural technology company that develops and licenses plant traits to seed companies, today announced key leadership changes pursuant to the Company’s previously announced succession planning strategy. As part of this plan, Craig Wichner, a board member since November 2025, has been appointed as the Company’s Chief Executive Officer. Peter Beetham, who has served as the Company’s Interim Chief Executive Officer, will continue his role as the Company’s President and Chief Operating Officer. Concurrently, both Mr. Wichner and Dr. Beetham resigned from the Cibus Board of Directors as part of this reorganization and plan.
“When Craig joined the Board, we recognized his exceptional combination of financial acumen, strategic discipline, and industry insight and leadership,” said Mark Finn, Chairman of the Board. “With his proven track record of delivering results and creating value, and his demonstrated leadership capabilities, including through his time on the Board, we are confident Craig is the right person to lead Cibus forward in our next stage as we focus on the execution of the Company’s near-term commercialization targets. Craig’s experience will be invaluable as we also execute our capital strategy to drive longer-term value creation through realization of our vision for the future of agriculture.”
“I also want to acknowledge and thank Peter for stepping into the role of Interim Chief Executive Officer over the past fifteen months, shepherding the Company to the precipice of its initial commercialization targets while raising over
“When I joined the Board last November, I saw a company with breakthrough technology and a clear path to put it to work," said Mr. Wichner. "My immediate focus is execution: getting Cibus' improved traits into customers' hands, converting our near-term commercialization targets into revenue, and maintaining the capital discipline to get there. Cibus is at a pivot point of real opportunity, and I am honored to lead it."
Dr. Beetham stated, “It is a pivotal moment for Cibus and I believe Cibus is fortunate to have Craig lead us into this next phase of growth and I am excited to work with him.”
Mr. Wichner is the Founder and Managing Partner of Farmland LP, a leading U.S. farmland investment management firm with more than
About Cibus
Cibus (Nasdaq: CBUS) is a leader in developing traits (characteristics) that address critical productivity, yield and sustainability challenges. Cibus' proprietary high-throughput gene editing technologies drive its long-term focus on productivity traits for farmers for the major global row crops. Cibus is not a seed company. It is a technology company that uses its gene editing technologies to develop plant traits at a fraction of the time and cost of conventional breeding and to license them to customers in exchange for royalties.
About the Cibus Trait Machine™ process and Rapid Trait Development System™
A key element of Cibus’ technology breakthrough is its high throughput breeding process (referred to as the Trait Machnine™ process). Cibus improves a crop by editing it directly, instead of crossbreeding plants over many generations and waiting years for the right trait to show up. It takes a single cell from a seed company's best existing variety, edits that cell's genes to add the trait the customer wants, and grows that one cell into a full plant carrying the edit. It is the first standardized, semi-automated system to do this. Cibus calls it the Trait Machine™ process, the crop-specific form of its core technology, the Rapid Trait Development System (RTDS®). The seed company keeps the prize variety it already spent years developing, and Cibus simply adds the improvement, far faster and cheaper than conventional breeding, then licenses it back to the customer. Cibus believes that RTDS and the Trait Machine process represent the technological breakthrough in plant breeding that is the ultimate promise of plant gene editing: high- throughput gene editing systems operating as an extension of seed company breeding programs. In 2024, the Trait Machine process was cited by Fast Company Magazine as one of the most innovative products in 2024.
Forward Looking Statements
This press release contains "forward-looking statements" within the meaning of applicable securities laws, including The Private Securities Litigation Reform Act of 1995. All statements, other than statements of present or historical fact included herein, including statements regarding Cibus' operational and financial performance, Cibus' strategy, future operations, prospects, and plans, are forward-looking statements. Forward-looking statements may be identified by words such as "anticipate," "believe," "intend," "expect," "plan," "scheduled," "could," "would" and "will," or the negative of these and similar expressions.
These forward-looking statements are based on the current expectations and assumptions of Cibus' management about future events, which are based on currently available information. These forward-looking statements are subject to numerous risks and uncertainties, many of which are difficult to predict and beyond the control of Cibus. Cibus' actual results, level of activity, performance, or achievements could be materially different than those expressed, implied, or anticipated by forward-looking statements due to a variety of factors, including, but not limited to: Cibus' need for additional near-term funding to finance its activities and challenges in obtaining additional capital on acceptable terms, or at all; changes in expected or existing competition; challenges to Cibus' intellectual property protection and unexpected costs associated with defending intellectual property rights; increased or unanticipated time and resources required for Cibus' platform or trait product development efforts; Cibus' reliance on third parties in connection with its development activities, including reliance on partner-funding and/or support for the advancement of its Sustainable Ingredients program; challenges associated with Cibus' ability to effectively license its productivity traits and sustainable ingredient products; the risk that farmers do not recognize the value in germplasm containing Cibus' traits or that farmers and processors fail to work effectively with crops containing Cibus' traits; delays or disruptions in the Company's platform or trait product development efforts, particularly insofar as they affect the Company's strategic priority programs; challenges that arise in respect of Cibus' production of high-quality plants and seeds cost effectively on a large scale; Cibus' dependence on distributions from Cibus Global, LLC to pay taxes and cover its corporate and overhead expenses; regulatory developments that disfavor or impose significant burdens on gene editing processes or products; Cibus' ability to achieve commercial success; commodity prices and other market risks facing the agricultural sector; technological developments that could render Cibus' technologies obsolete; changes in macroeconomic and market conditions, including inflation, supply chain constraints, and rising interest rates; dislocations in the capital markets and challenges in accessing liquidity and the impact of such liquidity challenges on Cibus' ability to execute on its business plan; the Company's assessment of the period of time through which its financial resources will be adequate to support operations; and other important factors discussed in the "Risk Factors" section of Cibus' Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the "SEC") on March 17, 2026, as may be updated from time-to-time in Cibus' subsequently filed Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. Should one or more of these risks or uncertainties occur, or should underlying assumptions prove incorrect, actual results and plans could differ materially from those expressed in any forward-looking statements.
In addition, the forward-looking statements included in this press release represent Cibus' views as of the date hereof. Cibus specifically disclaims any obligation to update such forward-looking statements in the future, except as required under applicable law. These forward-looking statements should not be relied upon as representing Cibus' views as of any date subsequent to the date hereof.
CIBUS CONTACTS:
INVESTOR RELATIONS
Jeff Sonnek
jeff.sonnek@icrinc.com
MEDIA RELATIONS
Colin Sanford
colin@bioscribe.com
203-918-4347
